Session

Late-breaking Abstracts II: Upper GI and IBD

DAVID AGAINST GOLIATH: DIRECT COMPARISON OF HAND-HELD BOWEL SONOGRAPHY AND MAGNETIC RESONANCE ENTEROGRAPHY FOR DIAGNOSIS OF CROHN’S DISEASE
DAVID AGAINST GOLIATH: DIRECT COMPARISON OF HAND-HELD BOWEL SONOGRAPHY AND MAGNETIC RESONANCE ENTEROGRAPHY FOR DIAGNOSIS OF CROHN’S DISEASE

DEVELOPMENT OF A CORE DESCRIPTOR SET FOR CROHN’S ANAL FISTULA - THE ENIGMA CODE STUDY
DEVELOPMENT OF A CORE DESCRIPTOR SET FOR CROHN’S ANAL FISTULA - THE ENIGMA CODE STUDY

DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY
DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY

TREATMENT OF PERIANAL FISTULAS IN CROHN’S DISEASE: ANTI-TNF WITH SURGICAL CLOSURE VERSUS ANTI-TNF ALONE (PISA-II) - A PATIENT PREFERENCE RCT
TREATMENT OF PERIANAL FISTULAS IN CROHN’S DISEASE: ANTI-TNF WITH SURGICAL CLOSURE VERSUS ANTI-TNF ALONE (PISA-II) - A PATIENT PREFERENCE RCT

ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN CELIAC PATIENTS UNDERGOING GLUTEN CHALLENGE
ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN CELIAC PATIENTS UNDERGOING GLUTEN CHALLENGE

DAVID AGAINST GOLIATH: DIRECT COMPARISON OF HAND-HELD BOWEL SONOGRAPHY AND MAGNETIC RESONANCE ENTEROGRAPHY FOR DIAGNOSIS OF CROHN’S DISEASE
DAVID AGAINST GOLIATH: DIRECT COMPARISON OF HAND-HELD BOWEL SONOGRAPHY AND MAGNETIC RESONANCE ENTEROGRAPHY FOR DIAGNOSIS OF CROHN’S DISEASE

Late-breaking Abstracts II: Upper GI and IBD  et al.

TREATMENT OF PERIANAL FISTULAS IN CROHN’S DISEASE: ANTI-TNF WITH SURGICAL CLOSURE VERSUS ANTI-TNF ALONE (PISA-II) - A PATIENT PREFERENCE RCT
TREATMENT OF PERIANAL FISTULAS IN CROHN’S DISEASE: ANTI-TNF WITH SURGICAL CLOSURE VERSUS ANTI-TNF ALONE (PISA-II) - A PATIENT PREFERENCE RCT

Late-breaking Abstracts II: Upper GI and IBD  et al.

ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN CELIAC PATIENTS UNDERGOING GLUTEN CHALLENGE
ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN CELIAC PATIENTS UNDERGOING GLUTEN CHALLENGE

Late-breaking Abstracts II: Upper GI and IBD  et al.

DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY
DUPILUMAB EFFICACY AND SAFETY UP TO 52 WEEKS IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A AND C OF A RANDOMIZED, PLACEBO-CONTROLLED, THREE-PART, PHASE 3 LIBERTY EOE TREET STUDY

Late-breaking Abstracts II: Upper GI and IBD  et al.

DEVELOPMENT OF A CORE DESCRIPTOR SET FOR CROHN’S ANAL FISTULA - THE ENIGMA CODE STUDY
DEVELOPMENT OF A CORE DESCRIPTOR SET FOR CROHN’S ANAL FISTULA - THE ENIGMA CODE STUDY

Late-breaking Abstracts II: Upper GI and IBD  et al.

Item 1 - 10 / 10
1